Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprascapular Nerve Block vs Infiltration in Glenohumeral Arthritis
NCT03794505Phase 3Completed
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Apr 2018
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of ropivacaine in glenohumeral arthritis (GHA) (2 arms), sponsored by Instituto Mexicano del Seguro Social. Primary endpoint: Visual Analog Scale for Pain at 6 months. Started Apr 2018; status: completed.
02
Drugs
ropivacaine
03
Conditions
glenohumeral arthritis (GHA)
Beyond the preview
Go deeper on NCT03794505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794505.